Actively Recruiting
Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy
Led by Mahidol University · Updated on 2025-02-27
140
Participants Needed
1
Research Sites
55 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A study comparing efficacy of olanzapine versus placebo to prevent nausea and vomiting from moderate emetic risk chemotherapy
CONDITIONS
Official Title
Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed cancer patients starting first dose of oxaliplatin, irinotecan, or carboplatin
- Age greater than 18 years old
You will not qualify if you...
- Pregnancy or breastfeeding
- Vomiting episode within the last 24 hours
- Gut obstruction
- Uncontrolled brain metastasis
- Allergy to or current use of olanzapine
- Receiving moderate or high emetogenic chemotherapy on days 2 to 5
- Total bilirubin greater than 2 mg/dl or creatinine clearance less than 30 ml/min
- Unable to swallow medication
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Faculty of Medicine Siriraj Hospital, Mahidol University
Bangkok, Bangkok, Thailand, 10700
Actively Recruiting
Research Team
S
Suthinee Ithimakin Ithimakin, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here